Compare PAYS & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAYS | EOLS |
|---|---|---|
| Founded | 2001 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 375.7M | 407.0M |
| IPO Year | 2020 | 2018 |
| Metric | PAYS | EOLS |
|---|---|---|
| Price | $8.29 | $6.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $9.42 | ★ $15.50 |
| AVG Volume (30 Days) | 591.7K | ★ 757.7K |
| Earning Date | 05-12-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 85.71 | 1.23 |
| EPS | ★ 0.09 | N/A |
| Revenue | $24,120,434.00 | ★ $297,176,000.00 |
| Revenue This Year | $33.83 | $13.27 |
| Revenue Next Year | $14.89 | $17.62 |
| P/E Ratio | $95.11 | ★ N/A |
| Revenue Growth | N/A | ★ 11.61 |
| 52 Week Low | $3.08 | $3.86 |
| 52 Week High | $8.88 | $10.20 |
| Indicator | PAYS | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 64.85 | 53.05 |
| Support Level | $5.01 | $6.44 |
| Resistance Level | N/A | $6.95 |
| Average True Range (ATR) | 0.42 | 0.31 |
| MACD | 0.10 | -0.03 |
| Stochastic Oscillator | 82.93 | 37.22 |
PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The Company creates customized payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The company's revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, and settlement income.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.